JP2017520590A - Pharmaceutical formulation - Google Patents

Abstract

The present invention relates to the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile or any pharmaceutically acceptable thereof. The invention relates to a pharmaceutical formulation for oral administration comprising a salt and a method for producing said solid pharmaceutical formulation.

Description

  The present invention relates to the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile or any pharmaceutically acceptable thereof. The invention relates to pharmaceutical formulations for oral administration, including salts. The invention further relates to a method for producing said solid pharmaceutical formulation.

  Compound 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile and its preparation method are disclosed in International Publication No. WO2007 / 024945. The contents of which are incorporated herein by reference. Said compound is represented by formula (1) and is referred to herein as a drug or a compound of formula (1).

  The compound of formula (1) has adrenal hormone-modifying properties and therapeutically treats a subject or disorder characterized by increased stress hormone levels and / or decreased androgen hormone levels in the subject. It can be used by administering an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof.

  Further, the compound of formula (1) comprises administering to a subject a therapeutically effective amount of a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, heart failure, cachexia, Can be used for the treatment of acute coronary syndrome, chronic stress syndrome, Cushing syndrome, or metabolic syndrome.

  Said medical use of the compound of formula (1) is described in WO 2011/088188, the contents of which are incorporated herein by reference.

  Several crystalline and amorphous forms of the compound of formula (1) and methods for preparing said forms are described in WO 2013/109514, the contents of which are hereby incorporated by reference. .

  However, no specific pharmaceutical composition or formulation for delivering a compound of formula (1) to a patient has been previously described.

  Because any active pharmaceutical ingredient has its own physical, chemical, and pharmacological properties, suitable pharmaceutical compositions and formulations must be individually designed for each new active pharmaceutical ingredient.

Designing pharmaceutical compositions, pharmaceutical formulations, and profitable pharmaceutical manufacturing processes of the compound of formula (1) is particularly difficult for (among other reasons) the following reasons.
Said compound is very cohesive, especially in its phosphate form, and is therefore influenced by a strong tendency to aggregate. This aggregation has been found to be responsible for inadequate and non-uniform drug distribution within the formulation with other ingredients.

  Furthermore, it has been experienced that the drugs have poor pharmaceutical processability. For example, it has been experienced that it cannot be sifted and has poor fluidity (ffc 1.1). The compound has a very low drug bulk density (0.1-0.3 g / mL), especially in its phosphate form, which results in poor processability, eg poor flow, and the compound Associated with the problem of the need for a special compaction step in manufacturing for the purpose of formulating a reasonably sized oral formulation for the convenience of patients who have to swallow the drug product.

Also, due to its amine functionality, the compounds are affected by chemical instability and incompatibility with other components.
In addition, the drug is hygroscopic, especially in its phosphate form, which is also associated with stability problems.

  It is therefore difficult to design a pharmaceutical composition of the compound of formula (1) that is pharmaceutically processable and to design a pharmaceutical formulation of an acceptable size that is stable and can be swallowed. is there. Designing a manufacturing process that allows the compound of formula (1) to be reliably produced on a profitable scale into a pharmaceutical formulation that meets the high quality standards of human medicine on a commercial scale is It is even more difficult.

  One of these difficulties was identifying an appropriate filler. There are basically three fillers used predominantly in the pharmaceutical field: lactose, mannitol, and microcrystalline cellulose (MCC). However, it has been found that the use of lactose as a filler results in chemical degradation products after compression of the compound of formula (1) into tablets. The use of mannitol as an intragranular filler resulted in stickiness problems and ribbon discoloration during the compaction step. Since MCC is known to be associated with drug absorption effects due to its amorphous region, the use of MCC was considered unsuitable as a filler for compounds of formula (1). Since MCC has a negatively charged surface, the absorption effect is particularly problematic for cationic drugs such as the compound of formula (1). Also in this regard, the low bulk density (corresponding to the high surface area) of the cationic compound of formula (1) is problematic and makes it more susceptible to the absorption effect. In particular, at low dosage strengths, the absorption effect may result in a significant loss of drug availability. As a result, all established fillers must be ignored in the design of pharmaceutical compositions and pharmaceutical formulations of the compound of formula (1).

  In view of the difficulties and considerations listed above, the inventors have discovered that in an unintuitive test, it is possible to use MCC as a filler for the formulation of compounds of formula (1). It was amazing. It has further surprisingly been found that when the compound of formula (1) is blended with MCC, the problematic very cohesive drug is transformed into a very fully pharmaceutically processable formulation.

  In view of these surprising discoveries, the inventors together with this, provide the invention in its following aspects.

In accordance with the first aspect of the invention,
(A) Formula (1)

The drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof as defined by And (b) a pharmaceutical formulation for oral administration comprising at least 30% by weight of microcrystalline cellulose based on the total weight of the pharmaceutical formulation.

  In accordance with the second aspect of the present invention, the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile is combined with microcrystalline cellulose. There is provided a method of preparing said pharmaceutical formulation comprising formulating.

  According to a third aspect of the present invention, there is provided a pharmaceutical formulation obtainable by said method.

  The invention will now be described and illustrated in further detail.

  In an embodiment of the invention, the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile is a compound of the formula herein. Also referred to as compound (1), it exists as the (R) -enantiomer of 4- [6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile. However, it can also exist as the (S) -enantiomer of the compound or as a mixture of the enantiomers. Preferably, the drug is at least 50 based on the total amount of compound 4- [6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile in the pharmaceutical formulation. %, More preferably at least 70%, even more preferably at least 90%, even more preferably at least 95%, even more preferably at least 98%, (R) -enantiomer 4-[(5R)- Present as 6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile.

  In aspects of the invention, the drug is present in its free form or in any pharmaceutically acceptable salt, complex, co-crystal, hydrate, or solvate form thereof.

In one embodiment, the compound of formula (1) exists in its free base form.
In another embodiment, the compound of formula (1) is present as a phosphate, in another embodiment as a monophosphate, and in another embodiment as an anhydrous monophosphate (1: 1 Molar ratio of compound of formula (1) and phosphoric acid). Monophosphate is also called dihydrogen phosphate.

  In one embodiment, the compound of formula (1) has at least one of the following characteristic peaks (2-theta, refraction angle, ± 0.2 °): 12.9 °, 16.3 °, 20.4 ° It exists as an anhydrous monophosphate in a polymorphic form characterized by an XRPD (X-ray powder diffractometry) pattern including one or all. Said polymorphic form is described as “Form A” in WO 2013/109514 A1. This latter disclosure provides a method of preparation of this form, further details the characterization of this form (Example 1), and is incorporated herein by reference.

  In an aspect of the invention, the drug is calculated in the pharmaceutical formulation based on its free base, based on the total weight of the pharmaceutical formulation, 0.5-20% by weight, preferably 0.5-10% by weight, More preferably 1-8% by weight, even more preferably 4 ± 1% by weight.

  In an embodiment of the invention, the pharmaceutical formulation comprises microcrystalline cellulose (European Pharmacopoeia, US Pharmacopoeia / National Pharmacopoeia, Japanese Pharmacopoeia). In an embodiment of the present invention, the MCC is at least 30%, 30-95%, 40-95%, 50-95%, 60-95%, 70-95%, 30-90%, 40-90%, It exists up to 50-90%, 60-90%, 70-90%, 30-85%, 40-85%, 50-85%, 60-85%, or 70-85%. In a preferred embodiment, the MCC is 30-95 wt%, in a more preferred embodiment 50-90 wt%, in an even more preferred embodiment 70-85 wt%, even more preferred based on the total weight of the pharmaceutical formulation. In the form it is present at 77 ± 7% by weight.

  The MCC may have an average particle size of 30-300 microns, 45-180 microns, 70-130 microns, or 100 ± 15 microns as measured by laser diffraction, wherein the particle size is measured by laser light diffraction. The

  The MCC may have a loose bulk density of 0.2-0.5 g / mL, 0.25-0.4 g / mL, or 0.31 ± 0.03 g / mL.

In an exemplary embodiment, the MCC has an average particle size of 100 ± 15 microns and a loose bulk density of 0.31 ± 0.03 g / mL. The quality MCC is FMC BioPolymer's Avicel PH102 (nominal particle size 100 microns, moisture 3.0-5.0%, loose bulk density 0.28-0.33 g / cc), or JRS Pharma's Vivapur102 ( JRS = J. Rettenmeier & Sonne, an average particle size of 100 microns by laser diffraction, a bulk density of 0.28 to 0.33 g / cm ³ ), and is also referred to herein as cellulose MK GR. This quality provides excellent tablet properties, such as excellent tablet hardness.

  The advantage of using MCC in the composition of a pharmaceutical formulation comprising a drug compound of formula (1) is that there is no chemical degradation reaction as observed for lactose and stickiness and discoloration problems as observed for mannitol There is no. Furthermore, the advantage of MCC is that it converts highly aggregating drugs, especially phosphates of highly agglomerated compounds of formula (1), into a pharmaceutically well-processable compounding material. . For example, in the absence of MCC, the drug cannot be screened through a 0.8 mm mesh, for example, even though its primary particle size (about 4 microns) is smaller than the mesh size. Due to the high tendency to agglomerate, the drug forms larger secondary particle aggregates (sizes of up to 1 mm) that no longer pass through the sieve. However, for example, the drug phosphate of the compound of formula (1) is about 1: 1, about 1: 1.5, about 1: 2, about 1: 5, about 1: 6 in a weight ratio (monophosphate When blended with MCC or more MCC (weight of compound of formula (1) as salt: weight of MCC), a blended material is obtained that can be easily screened through a 0.8 mm mesh.

  The pharmaceutical preparation according to the invention may further comprise a lubricant, preferably comprising a lubricant, preferably the lubricant is silicon dioxide, more preferably the lubricant is colloidal silicon dioxide (European Pharmacopoeia, US Pharmacopoeia). / National Drug Collection, Japanese Pharmacopoeia).

  The lubricant is present at 0.1-5% by weight, preferably 0.3-1.5% by weight, more preferably 0.6 ± 0.3% by weight, based on the total weight of the pharmaceutical formulation Further provided is a pharmaceutical formulation according to

Preferably, the lubricant is colloidal silicon dioxide, also called hydrophilic fumed silica, having a surface area with a BET of 200 ± 25 m ² / g, for example sold under the trade name Aerosil 200 Pharma by Evonik (formerly Degussa). (BET surface area 200 ± 25 m ² / g, loss on drying ≦ 2.5% by weight, pH 3.5-5.5).

  When the inventors of the present invention produce tablets of phosphate of the drug compound of formula (1) without a lubricant or with only a low level of lubricant (only about 0.2%), these tablets Occasionally, we experienced capping problems (the top of the tablet, ie the top cap cracked along the edge of the cap and the tablet band) and low tablet hardness values. However, with about 0.5 wt.% Lubricant colloidal silicon dioxide based on the total final formulation for tablet compression, the capping tendency was removed even at high compression forces, and the tablet hardness value increased significantly. . Therefore, the presence of a lubricant in the pharmaceutical composition of the compound of formula (1) has advantages, especially when the lubricant is present extragranularly.

  To prevent capping problems with tablets containing the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile according to the present invention. Use of colloidal silicon dioxide is provided.

In a preferred embodiment, the pharmaceutical formulation according to the invention comprises
(A) The drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazole-5, preferably present as a phosphate, more preferably as a monophosphate Yl] -3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof,
(B) at least 30% by weight of microcrystalline cellulose, based on the total weight of the pharmaceutical formulation, and (c) a lubricant, preferably colloidal silicon dioxide.

In a more preferred embodiment, the pharmaceutical formulation according to the invention is based on the total weight of said pharmaceutical formulation,
(A) 0.5-20% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c, present as a monophosphate, calculated on the free base ] Imidazol-5-yl] -3-fluorobenzonitrile,
(B) 30 to 95% by weight of microcrystalline cellulose,
(C) contains 0.1 to 5% by weight of colloidal silicon dioxide.

In a more preferred embodiment, the pharmaceutical formulation according to the invention is based on the total weight of said pharmaceutical formulation,
(A) 0.5-20% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c, present as a monophosphate, calculated on the free base ] Imidazol-5-yl] -3-fluorobenzonitrile,
(B) 30-95 wt%, 50-95 wt%, 70-90 wt%, or 80 ± 5 wt% microcrystalline cellulose,
(C) contains 0.1 to 5% by weight of colloidal silicon dioxide.

More specifically, in a preferred embodiment of the invention, the pharmaceutical dosage comprises an internal phase (also called intragranular phase) and an external phase (also called extragranular phase),
The internal phase is based on the total weight of the internal phase
(A) 0.5-20% by weight, preferably 5-15% by weight, more preferably 10 ± 2% by weight of the drug 4-[(5R) present as monophosphate, calculated on the free base ) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile, and (b) 50-95 wt%, preferably 70-90 wt%, and more Preferably it contains 80 ± 5% by weight of microcrystalline cellulose and the external phase is based on the total weight of the final formulation,
(C) 0.1 to 5% by weight, preferably 0.2 to 1% by weight, more preferably 0.5 ± 5% by weight of colloidal silicon dioxide.

In a preferred embodiment of the invention, the pharmaceutical dosage comprises an internal phase (also called intragranular phase) and an external phase (also called extragranular phase),
The internal phase is based on the total weight of the internal phase
(A) 5-15% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazole present as monophosphate, calculated on the free base -5-yl] -3-fluorobenzonitrile, and (b) 70-90 wt% microcrystalline cellulose, and the external phase is based on the total weight of the final formulation,
(C) contains 0.1 to 5% by weight of colloidal silicon dioxide.

In a more preferred embodiment of the invention, the pharmaceutical dosage comprises an internal phase (also called intragranular phase) and an external phase (also called extragranular phase),
The internal phase is based on the total weight of the internal phase
(A) 5-15% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazole present as monophosphate, calculated on the free base -5-yl] -3-fluorobenzonitrile, and (b) 70-90 wt% microcrystalline cellulose, and the external phase is based on the total weight of the final formulation,
(C) 0.2 to 1% by weight of colloidal silicon dioxide.

The term internal phase or intragranular phase refers to the portion of the composition that is granulated (eg, by wet granulation) or compacted (eg, by roller compaction).
The term external phase or extragranular phase refers to the portion of the composition that is added to the granulated or compacted internal phase to form the final blend with the internal phase.

  The term final formulation refers to the mixed internal and external phases ready to be compressed into tablets or filled into capsules.

  The pharmaceutical formulation according to the invention may further comprise mannitol, preferably it further comprises mannitol, more preferably it comprises mannitol in the external phase.

  In a preferred embodiment of the invention, the mannitol is present in a pharmaceutical formulation in an amount of 3-40% by weight, preferably 5-40% by weight, more preferably 5-15% by weight, based on the total weight of the pharmaceutical formulation. More preferably at 10 ± 2% by weight.

  More specifically, in a preferred embodiment of the invention, the amount of the mannitol is present in the external phase.

  Preferably, the mannitol is of a quality suitable for direct compression (also referred to herein as mannitol DC), such as Merck's Parteck M200.

In a particularly preferred embodiment of the invention, the pharmaceutical formulation is based on the total weight of said pharmaceutical formulation,
(A) 1 to 8% by weight, preferably 4 ± 1% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo, present as monophosphate, calculated on the free base [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile,
(B) 30-90% by weight, preferably 77 ± 7% by weight microcrystalline cellulose,
(C) 0.1-5 wt%, preferably 0.6 ± 0.3 wt% colloidal silicon dioxide, and (d) 5-40 wt%, preferably 10 ± 2 wt% mannitol, Optionally,
(E) 0.1-5% by weight, preferably 2 ± 0,5% by weight of disintegrant, preferably croscarmellose sodium (also referred to herein as Na-CMC XL), eg FMC BioPolymer Ac- Di-Sol, and (f) 0.1-3 wt%, preferably 1.5 ± 0.5 wt% lubricant, preferably further magnesium stearate.

  The pharmaceutical formulation according to the invention may be in the form of a powder, capsule or tablet, preferably it is in the form of a tablet.

  In a preferred embodiment of the invention, the pharmaceutical formulation is in the form of a tablet and the tablet is coated with a film, ie a film-coated tablet, preferably said film is polyvinyl alcohol, and optionally plasticizers and pigments ( For example, Colorcon's Opadry Premix).

  In accordance with the second aspect of the invention, the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile is microcrystalline cellulose ( There is provided a method of preparing a pharmaceutical formulation as described herein above, comprising combining with MCC).

  Preferably, the compounding of the drug with MCC is performed as a first process step prior to any screening, screening, compaction, or compression step.

  Said compounding the drug with MCC, with MCC as the sole excipient, or with MCC in combination with a lubricant, preferably colloidal silicon dioxide, and optionally in combination with a disintegrant, You can go.

  Preferably, the method further comprises the use of a lubricant to prepare a tableting formulation.

In a preferred embodiment of the invention, the method comprises the following process steps:
(1) Drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile with microcrystalline cellulose, and optionally colloid A mechanically compactable formulation by compounding with further components such as silicon dioxide, disintegrant, preferably croscarmellose, and lubricant, preferably magnesium stearate, said component constituting the internal phase Get the steps,
(2) compacting the machine compactable formulation by dry granulation, preferably by roller compaction, to obtain a compacted material;
(3) the compacted material with colloidal silicon dioxide and optionally a filler, preferably microcrystalline cellulose and / or mannitol, more preferably microcrystalline cellulose and mannitol, a disintegrant, preferably croscarmellose Compounding with sodium and a further component such as a lubricant, preferably magnesium stearate, said component constituting the external phase, to obtain a mechanically compressible formulation (also called final formulation);
(4) The mechanically compressible formulation is further characterized by compressing it by use of a tablet press to obtain tablets.

In a particularly preferred embodiment, the method comprises the following process steps:
(1) Drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile with microcrystalline cellulose, colloidal silicon dioxide, and Blending with a disintegrant, preferably croscarmellose, to obtain a blend;
(2) selecting the blend of step (2) preferably through 0.5-2 mm, more preferably 0.6-1.0 mm, even more preferably 0.8 mm;
(3) blending the selected blend of step (3) with a lubricant, preferably magnesium stearate, to obtain a mechanically compactable blend;
(4) the step of compacting the mechanically compactable composition of step (3) by dry granulation, preferably by roller compaction;
(5) screening the compacted formulation of step (4) preferably through 0.5-2 mm, more preferably 0.6-1.0 mm, and even more preferably 0.8 mm;
(6) combining the compacted and screened material of step (5) with microcrystalline cellulose, colloidal silicon dioxide, mannitol, and a disintegrant, preferably croscarmellose sodium, to obtain a formulation;
(7) blending the blend of step (6) with a lubricant, preferably magnesium stearate, to obtain a mechanically compressible blend;
(8) compressing the mechanically compressible formulation of step (7) by use of a tablet press to obtain a core tablet;
(9) Further characterized by the step of coating the core tablet of step (8) to obtain a film-coated tablet.

  According to a third aspect of the present invention there is provided a pharmaceutical formulation obtainable by any of the method embodiments described herein above.

  According to a fourth aspect of the invention, the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile is pharmaceutically processed. The use of microcrystalline cellulose to convert to a possible material is provided.

  According to a fifth aspect of the present invention, in tablets containing the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile The use of colloidal silicon dioxide to prevent capping problems is provided.

  According to a sixth aspect of the present invention there is provided a pharmaceutical formulation for use in the treatment of Cushing disease or Cushing syndrome.

  According to a seventh aspect of the present invention, there is provided a method for treating a disease comprising administering a therapeutically effective amount of a pharmaceutical formulation to a patient suffering from Cushing disease or Cushing syndrome.

Example 1: Tablet Production According to the composition shown in Table 1 below, a film-coated tablet of drug compound monophosphate of formula (1) is produced. The same composition is used to produce 5 mg, 10 mg, and 20 mg dosage strength tablets.

Core tablet manufacture consists of the following dry granulation, sizing, blending, and tableting steps.
1. About 50% (part 1) of the internal phase microcrystalline cellulose is added to a suitable container and the total amount of drug followed by the remaining 50% (part 2) of the internal phase microcrystalline cellulose, Na-CMC-XL, and Aerosil. To obtain a drug sandwich between the two layers of excipients and blend this mixture in a diffusion mixer.
2. The formulation of Step 1 is screened through a screening mill (Frewitt MGW520 / 6, 0.8 mm net, round line, 57-104 rpm) equipped with a vibrating bar.
3. Sieve the magnesium stearate (hand sieve, mesh size 0.8 mm), add it to the Step 2 material, and blend the mixed material in a diffusion mixer.
4). Step 3 blended dry granulator, for example, roller compactor (Roller Bepex Hosokawa Pharmapactor L-200 / 30P, 18 kN compaction force, 3-6 rpm roller speed (rotary compaction roll), rotational screw speed is compacted Compacted within (adapted to the compaction force).
5. The compacted material from step 4 is screened with a sorting mill (Frewitt MGW520 / 6, 0.8 mm net, round line, 57-104 rpm) equipped with a vibrating bar.
6). Sift microcrystalline cellulose, mannitol, Na-CMC-XL, and Aerosil (hand sieve, 0.8 mm mesh size) and add it to the Step 5 material and blend in a diffusion mixer.
7). Sieve the magnesium stearate (hand sieve, 0.8 mm mesh size), add it to the Step 6 material, and blend the mixed material in a diffusion mixer.
8). The final formulation of Step 7 is a rotary tablet press (FETTE1200i TP09, 8 Euro B punch, setting the compression force to 1-40 kN to match the target hardness of 80 N for 5 mg tablets, 100 N for 10 mg tablets, 160 N for 20 mg tablets) Compress using
9. Coat the core tablet of step 8 in a perforated pan coater (Glatt GC750 or 1000).

  Conventional final formulations of various dosage strengths can be made by normal granulation and blending. The final formulation is divided according to the final core tablet batch size per dose strength and compressed on a tablet press to obtain the final core tablet.

  The resulting tablet core is coated with a standard aqueous coating suspension in a side vented perforated coating pan.

Claims (18)

A pharmaceutical formulation for oral administration comprising:
(A) Formula (1)
4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof as defined by A pharmaceutical formulation comprising: (b) at least 30% by weight of microcrystalline cellulose, based on the total weight of the pharmaceutical formulation.   2. The pharmaceutical formulation according to claim 1, wherein the microcrystalline cellulose is present at 30-95% by weight, based on the total weight of the pharmaceutical formulation.   Pharmaceutical formulation according to claim 1 or 2, wherein the drug is present as a phosphate, preferably as a monophosphate.   4. The pharmaceutical formulation according to any one of claims 1 to 3, wherein the drug is present at 0.5 to 20% by weight, based on the total weight of the pharmaceutical formulation, calculated on the basis of its free base.   The pharmaceutical formulation according to any one of claims 1 to 4, further comprising a lubricant, preferably wherein the lubricant is silicon dioxide, more preferably the lubricant is colloidal silicon dioxide.   7. A pharmaceutical formulation according to claim 6, wherein the lubricant is present at 0.1-5% by weight, based on the total weight of the pharmaceutical formulation. (A) said drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile present as phosphate
The pharmaceutical formulation according to any one of claims 1 to 6, comprising (b) at least 30% by weight of microcrystalline cellulose, based on the total weight of the pharmaceutical formulation, and (c) colloidal silicon dioxide. Based on the total weight of the pharmaceutical formulation,
(A) 1 to 8% by weight of the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] present as a monophosphate, calculated on the free base Imidazol-5-yl] -3-fluorobenzonitrile,
(B) 30 to 95% by weight of the microcrystalline cellulose,
8. The pharmaceutical preparation according to claim 7, comprising (c) 0.3 to 1.5% by weight of the colloidal silicon dioxide.   The pharmaceutical formulation according to any one of claims 1 to 8, further comprising mannitol.   9. Pharmaceutical formulation according to claim 8, wherein the mannitol is present in 3-40% by weight, preferably 5-40% by weight, based on the total weight of the pharmaceutical formulation. Based on the total weight of the pharmaceutical formulation,
(A) Calculated on the basis of the free base, 4 ± 1% by weight of said drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] present as monophosphate Imidazol-5-yl] -3-fluorobenzonitrile,
(B) 77 ± 7% by weight of the microcrystalline cellulose,
(C) 0.6 ± 0.2% by weight of the colloidal silicon dioxide,
(D) containing 10 ± 2 wt% mannitol and optionally (e) 2 ± 0.5 wt% disintegrant, preferably croscarmellose sodium, and (f) 1.5 ± 0.5 wt A pharmaceutical formulation according to any one of the preceding claims, further comprising a% lubricant, preferably magnesium stearate.   Combining the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile with microcrystalline cellulose. A method for preparing a pharmaceutical formulation according to any one of 1 to 11.   13. The method of claim 12, wherein the blending of the drug with microcrystalline cellulose is performed as a first process step prior to any sieving, screening, compaction, or compression step.   14. A method according to claim 12 or 13, further comprising the use of a lubricant to prepare a tableting formulation. The following process steps,
(1) combining the drug with microcrystalline cellulose, and optionally further components such as lubricants, disintegrants, and lubricants, to obtain a machine compactable formulation;
(2) a step of obtaining a compacted material by compacting said mechanical compactable formulation by dry granulation, preferably by roller compaction;
(3) The compacted material is blended with colloidal silicon dioxide and optionally further components such as microcrystalline cellulose, mannitol, disintegrant, and lubricant to obtain a mechanically compressible blend. Step,
15. The method of claims 12-14, further characterized by the step of (4) compressing the mechanically compressible formulation by use of a tablet press to obtain a tablet.   The pharmaceutical formulation obtained by the method as described in any one of Claims 12-15.   A drug for converting the drug 4-[(5R) -6,7-dihydro-5H-pyrrolo [1,2-c] imidazol-5-yl] -3-fluorobenzonitrile into a pharmaceutically processable material. Use of crystalline cellulose.   17. A pharmaceutical formulation according to any one of claims 1 to 11 or claim 16 for use in the treatment of Cushing disease or Cushing syndrome.